BMPR2 and lymphoma: At the molecular level, miR-155 represses the growth-inhibitory effects of bone morphogenetic protein receptor type 2 (BMPR2) and TGF-β in DLBCL cells via direct targeting of SMAD5 [180], and, in a therapeutic view, ectopic delivery of anti-miR-155 leads to lymphoma regression in a xeno-transplant mouse model [181].